BiotechTube

olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolic Syndrome

Conditions

Metabolic Syndrome, Hypertension

Trial Timeline

Aug 1, 2008 → May 1, 2011

NCT ID
NCT00676845

About olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil

olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil is a phase 3 stage product being developed by Daiichi Sankyo for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00676845. Target conditions include Metabolic Syndrome, Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00676845Phase 3Completed

Competing Products

20 competing products in Metabolic Syndrome

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
85
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
77
14C-labeled YM178Astellas PharmaPhase 1
33
TRC150094Torrent PharmaceuticalsPhase 1/2
41
LY518674Eli LillyPhase 2
52
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
77
Metformin + PlaceboEli LillyApproved
85
Tirzepatide + SemaglutideEli LillyPre-clinical
23
LY3849891 + PlaceboEli LillyPhase 1
33
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
85
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaApproved
85
AZD2693 + PlaceboAstraZenecaPhase 1
33
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77
rosuvastatinAstraZenecaApproved
85
EfinopegdutideMerckPhase 2
52
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
52
Vericiguat + PlaceboMerckPhase 2
52
MetforminMerckPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85